| | | | | Donor governments and philanthropists pledged $2.6 billion on Tuesday to help fund a worldwide polio eradication plan that has taken decades to reach what global health specialists say is now the "last mile". | | |
| | | Perhaps no issue has divided the field of Democratic 2020 presidential hopefuls more than the debate over "Medicare for All." | | |
| | | The state of California on Monday sued e-cigarette maker Juul Labs Inc, alleging the San Francisco company engaged in a "systematic" and "wildly successful" campaign to attract teenagers to its nicotine devices. | | |
| | | Four Democratic leaders on the U.S. House of Representatives Energy and Commerce committee on Monday wrote Alphabet Inc's Google and Ascension Health demanding briefings by Dec. 6 on how patient data the hospital chain is storing on the cloud is used. | | |
| | | (Reuters Health) - Telling the difference between a teen's normal ups and downs and something bigger is among top challenges parents face in identifying youth depression, a new national poll suggests. | | |
| | | (Reuters Health) - States that expand public health benefits to cover low-income legal immigrants don't appear to experience a surge in immigrants moving to get medical coverage, a U.S. study suggests. | | |
| | | (Reuters Health) - With several small studies suggesting that the widely prescribed cholesterol-lowering drugs, statins, might be linked to memory loss in seniors, patients were understandably concerned. But a large new study finds no link between memory loss and the drugs. | | |
| | | (Reuters Health) - The inflammation-fighting drug colchicine, already a treatment for gout, dramatically reduces the odds of future cardiovascular problems in people who have just survived a heart attack, a large new study has concluded. | | |
| | | Portugal's Champalimaud Foundation announced on Monday the world's largest annual prize, worth 1 million euros, for research and clinical practices aiming to control or eradicate cancer. | | |
| | | German biotech company Morphosys said more patients would be recruited for a study testing its most advanced drug against a common type of blood cancer, following an encouraging interim data readout. | | |
| | | Novartis is exiting drug discovery at its Shanghai site and shifting its focus to drug development, saying accelerating approvals in China are pushing the Swiss company to dedicate the operation's resources to getting its medicines to market. | | |
|
| |
